|
MedChemExpress
molnupiravir mpv Molnupiravir Mpv, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/molnupiravir/Molnupiravir/pmc11745048-117-0-5 Average 95 stars, based on 1 article reviews
molnupiravir mpv - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
|
TargetMol
molnupiravir Molnupiravir, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/molnupiravir/Molnupiravir/10__1017_slash_s0885715624000599-34-0-7 Average 93 stars, based on 1 article reviews
molnupiravir - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Biosynth Carbosynth
molnupiravir ![]() Molnupiravir, supplied by Biosynth Carbosynth, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/molnupiravir/Molnupiravir/pm36842392-99-39-48 Average 93 stars, based on 1 article reviews
molnupiravir - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Selleck Chemicals
molnupiravir ![]() Molnupiravir, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/molnupiravir/Molnupiravir/pm37607058-278-5-7 Average 92 stars, based on 1 article reviews
molnupiravir - by Bioz Stars,
2026-11
92/100 stars
|
Buy from Supplier |
|
Tocris
molnupiravir ![]() Molnupiravir, supplied by Tocris, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/molnupiravir/Molnupiravir/pm39123296-204-7-8 Average 92 stars, based on 1 article reviews
molnupiravir - by Bioz Stars,
2026-11
92/100 stars
|
Buy from Supplier |
|
Shionogi
molnupiravir ![]() Molnupiravir, supplied by Shionogi, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/molnupiravir/molnupiravir/pm41920902-304-16-23 Average 86 stars, based on 1 article reviews
molnupiravir - by Bioz Stars,
2026-11
86/100 stars
|
Buy from Supplier |
|
EVA pharma
molnupiravir-eva capsule ![]() Molnupiravir Eva Capsule, supplied by EVA pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/molnupiravir/molnupiravir/10__21608_slash_ajps__2024__360414-119-11-6 Average 90 stars, based on 1 article reviews
molnupiravir-eva capsule - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
BioTherapeutics Inc
molnupiravir ![]() Molnupiravir, supplied by BioTherapeutics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/molnupiravir/molnupiravir/pmc09662684-441-11-1 Average 90 stars, based on 1 article reviews
molnupiravir - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Pine Tree Inc
molnupiravir [14] , Molnupiravir, supplied by Pine Tree Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/molnupiravir/molnupiravir/pmc08755553-193-7-30 Average 90 stars, based on 1 article reviews
molnupiravir - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Merck & Co
molnupiravir ![]() Molnupiravir, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/molnupiravir/molnupiravir/pmc08771611-157-31-34 Average 90 stars, based on 1 article reviews
molnupiravir - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Computational biology and chemistry
Article Title: Dual computational and biological assessment of some promising nucleoside analogs against the COVID-19-Omicron variant.
doi: 10.1016/j.compbiolchem.2022.107768
Figure Lengend Snippet: Fig. 2. RMSD trajectories (during a simulation period of 100 ns) of the α-carbon of amino acid residues of the protein (blue color) and the ligand (maroon color) in the protein-ligand complexes of the two NAs, riboprine and forodesine, and the two reference drugs, remdesivir and molnupiravir, respectively, with: (A) SARS-CoV- 2 RdRp "nsp12" enzyme cocrystallized with its protein cofactors nsp7 and nsp8 (PDB ID: 7BV2). (B) SARS-CoV-2 ExoN "nsp14" enzyme cocrystallized with its protein cofactor nsp10 (PDB ID: 7MC6). For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.
Article Snippet: While forodesine (Immucillin-H, CAS Registry Number: 209799–67–7), nelarabine (Arranon, CAS Registry Number: 121032–29–9), tecadenoson (CVT-510, CAS Registry Number: 204512–90–3), maribavir (1263W94, CAS Registry Number: 176161–24–3), vidarabine (Arabinosyladenine "Ara-A", CAS Registry Number: 5536–17–4), remdesivir (GS-5734, CAS Registry Number: 1809249–37–3), and
Techniques:
Journal: Computational biology and chemistry
Article Title: Dual computational and biological assessment of some promising nucleoside analogs against the COVID-19-Omicron variant.
doi: 10.1016/j.compbiolchem.2022.107768
Figure Lengend Snippet: Fig. 3. RMSF trajectories (along the different residue regions) of the α-carbon of amino acid residues of the protein in the protein-ligand complexes of the two NAs, riboprine and forodesine, and the two reference drugs, remdesivir and molnupiravir, respectively, with: (A) SARS-CoV-2 RdRp "nsp12" enzyme cocrystallized with its protein cofactors nsp7 and nsp8 (PDB ID: 7BV2). (B) SARS-CoV-2 ExoN "nsp14" enzyme cocrystallized with its protein cofactor nsp10 (PDB ID: 7MC6).
Article Snippet: While forodesine (Immucillin-H, CAS Registry Number: 209799–67–7), nelarabine (Arranon, CAS Registry Number: 121032–29–9), tecadenoson (CVT-510, CAS Registry Number: 204512–90–3), maribavir (1263W94, CAS Registry Number: 176161–24–3), vidarabine (Arabinosyladenine "Ara-A", CAS Registry Number: 5536–17–4), remdesivir (GS-5734, CAS Registry Number: 1809249–37–3), and
Techniques: Residue
Journal: Computational biology and chemistry
Article Title: Dual computational and biological assessment of some promising nucleoside analogs against the COVID-19-Omicron variant.
doi: 10.1016/j.compbiolchem.2022.107768
Figure Lengend Snippet: Fig. 4. Collective post-MD simulation analysis of the protein-ligand complexes properties (RMSD, rGyr, MolSA, SASA, and PSA) of the two NAs, riboprine and forodesine, and the two reference drugs, remdesivir and molnupiravir, respectively, with: (A) SARS-CoV-2 RdRp "nsp12" enzyme cocrystallized with its protein cofactors nsp7 and nsp8 (PDB ID: 7BV2). (B) SARS-CoV-2 ExoN "nsp14" enzyme cocrystallized with its protein cofactor nsp10 (PDB ID: 7MC6).
Article Snippet: While forodesine (Immucillin-H, CAS Registry Number: 209799–67–7), nelarabine (Arranon, CAS Registry Number: 121032–29–9), tecadenoson (CVT-510, CAS Registry Number: 204512–90–3), maribavir (1263W94, CAS Registry Number: 176161–24–3), vidarabine (Arabinosyladenine "Ara-A", CAS Registry Number: 5536–17–4), remdesivir (GS-5734, CAS Registry Number: 1809249–37–3), and
Techniques:
Journal: Computational biology and chemistry
Article Title: Dual computational and biological assessment of some promising nucleoside analogs against the COVID-19-Omicron variant.
doi: 10.1016/j.compbiolchem.2022.107768
Figure Lengend Snippet: Fig. 5. Histograms of the protein-ligand interactions fractions throughout the simulative interaction trajectories of the two NAs, riboprine and forodesine, and the two reference drugs, remdesivir and molnupiravir, respectively, with: (A) SARS-CoV-2 RdRp "nsp12" enzyme cocrystallized with its protein cofactors nsp7 and nsp8 (PDB ID: 7BV2). (B) SARS-CoV-2 ExoN "nsp14" enzyme cocrystallized with its protein cofactor nsp10 (PDB ID: 7MC6).
Article Snippet: While forodesine (Immucillin-H, CAS Registry Number: 209799–67–7), nelarabine (Arranon, CAS Registry Number: 121032–29–9), tecadenoson (CVT-510, CAS Registry Number: 204512–90–3), maribavir (1263W94, CAS Registry Number: 176161–24–3), vidarabine (Arabinosyladenine "Ara-A", CAS Registry Number: 5536–17–4), remdesivir (GS-5734, CAS Registry Number: 1809249–37–3), and
Techniques:
Journal: Computational biology and chemistry
Article Title: Dual computational and biological assessment of some promising nucleoside analogs against the COVID-19-Omicron variant.
doi: 10.1016/j.compbiolchem.2022.107768
Figure Lengend Snippet: Fig. 6. Plots of the distribution of the total number of interactions (contacts) in each trajectory framework of the protein-ligand complexes of the two NAs, riboprine and forodesine, and the two reference drugs, remdesivir and molnupiravir, respectively, with: (A) SARS-CoV-2 RdRp "nsp12" enzyme cocrystallized with its protein cofactors nsp7 and nsp8 (PDB ID: 7BV2). (B) SARS-CoV-2 ExoN "nsp14" enzyme cocrystallized with its protein cofactor nsp10 (PDB ID: 7MC6).
Article Snippet: While forodesine (Immucillin-H, CAS Registry Number: 209799–67–7), nelarabine (Arranon, CAS Registry Number: 121032–29–9), tecadenoson (CVT-510, CAS Registry Number: 204512–90–3), maribavir (1263W94, CAS Registry Number: 176161–24–3), vidarabine (Arabinosyladenine "Ara-A", CAS Registry Number: 5536–17–4), remdesivir (GS-5734, CAS Registry Number: 1809249–37–3), and
Techniques:
Journal: Computational biology and chemistry
Article Title: Dual computational and biological assessment of some promising nucleoside analogs against the COVID-19-Omicron variant.
doi: 10.1016/j.compbiolchem.2022.107768
Figure Lengend Snippet: Fig. 7. Cytotoxicity graphs obtained in the current study for: (a) Riboprine, (b) Forodesine, (c) Nelarabine, (d) Tecadenoson, (e) Maribavir, (f) Vidarabine, (g) Remdesivir, (h) Molnupiravir, and (i) DMSO.
Article Snippet: While forodesine (Immucillin-H, CAS Registry Number: 209799–67–7), nelarabine (Arranon, CAS Registry Number: 121032–29–9), tecadenoson (CVT-510, CAS Registry Number: 204512–90–3), maribavir (1263W94, CAS Registry Number: 176161–24–3), vidarabine (Arabinosyladenine "Ara-A", CAS Registry Number: 5536–17–4), remdesivir (GS-5734, CAS Registry Number: 1809249–37–3), and
Techniques:
Journal: Advanced biology
Article Title: Predicting Clinical Outcomes of SARS-CoV-2 Drug Efficacy with a High-Throughput Human Airway Microphysiological System.
doi: 10.1002/adbi.202300511
Figure Lengend Snippet: Figure 3. Differential response of PREDICT96-ALI to antiviral drugs. Comparison between the antiviral effects of six drug compounds, nirmatrelvir, molnupiravir, remdesivir, calpeptin, fluvoxamine, and amodiaquine, against SARS-CoV-2 infection in tissue from donor 0 4401 grown in PREDICT96-ALI. A) Effects of nirmatrelvir, molnupiravir, remdesivir, and calpeptin against SARS-CoV-2 USA-WA1/2020. B) Table shows inter- and intra-plate variability from PREDICT96-ALI over experimental time course (SARS-CoV-2 USA-WA1/2020). Coefficients of variation (% CV) were calculated from viral genome quantification data for each condition (n = 3 or 4 individual tissue devices per condition, 18 conditions total) and averaged across conditions at each time point. Plate 1 (top row) corresponds to the datasets represented in panel A, plate 2 is an independent experiment (data not shown). C) Image quantification of SARS-CoV-2 infected tissues nucleocapsid positive (+) cells shows tissue response to 5 drug compounds 6 days post inoculation (d.p.i.) of SARS-CoV-2 USA-WA1/2020 infection in donor 0 4401. Briefly, in tissues stained for nuclei (Hoechst) and SARS-CoV-2 nucleocapsid (N) protein, the Celigo software was used to quantify the percentage of nuclei corresponding cells to cell positive for the N. (D) Effects of nirmatrelvir, molnupiravir, remdesivir, amodiaquine and fluvoxamine against SARS-CoV-2 Omicron variant. (E) The table shows inter- and intra-plate variability as % CV from PREDICT96-ALI over experimental time course (Omicron variant). Plate 1 (top row) corresponds to the datasets represented in panel D, plate 2 is an independent experiment (data not shown). In panels (A) and (D): Antiviral drugs were diluted in media and added 2 h after infection and again on at 2 and 4 d.p.i. at the concentrations indicated. Apical sides of tissues were washed with HBSS to collect viral supernatant from which SARS-CoV-2 viral genomes were quantified by RT-qPCR. Data presented as mean ± standard error of the mean. n = 4 tissue devices per condition. Data collected from the same experiment panel A displayed in panel C and representative of 2 independent experiments. All bar graphs show mean ± standard deviation. Statistical significance determined by a two-way analysis of variance (ANOVA) with Dunnett’s test for multiple comparisons (comparing to infected vehicle control (A and D) or infected/untreated C)): p > 0.05; *p ≤0.05; **p ≤0.01; ***p ≤0.001; ****p ≤0.0001. Unlabeled lines indicate no significant difference. See also Figure S2 (Supporting Information).
Article Snippet: Antiviral Drug Dosing: Nirmatrelvir (MedChemExpress), PF-00835231 (MedChemExpress),
Techniques: Comparison, Infection, Staining, Software, Variant Assay, Quantitative RT-PCR, Standard Deviation, Control
[14] , Journal: Diabetes & Metabolic Syndrome
Article Title: An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19
doi: 10.1016/j.dsx.2022.102396
Figure Lengend Snippet: Results from molnupiravir MOVe-OUT trial in adults with mild-to-moderate COVID-19 [
Article Snippet: For example-primary outcome was all-cause hospitalization or
Techniques:
[14] , Journal: Diabetes & Metabolic Syndrome
Article Title: An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19
doi: 10.1016/j.dsx.2022.102396
Figure Lengend Snippet: Subgroups who appeared to have no benefit in hospitalization or death through day 29 with molnupiravir over placebo [
Article Snippet: For example-primary outcome was all-cause hospitalization or
Techniques:
[14] , Journal: Diabetes & Metabolic Syndrome
Article Title: An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19
doi: 10.1016/j.dsx.2022.102396
Figure Lengend Snippet: Comparative efficacy data of EUA/authorized # drugs for COVID-19 [
Article Snippet: For example-primary outcome was all-cause hospitalization or
Techniques: In Vitro
Journal: Diabetes & Metabolic Syndrome
Article Title: An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19
doi: 10.1016/j.dsx.2022.102396
Figure Lengend Snippet:
Article Snippet: For example-primary outcome was all-cause hospitalization or
Techniques: Infection
Journal: Diabetes & Metabolic Syndrome
Article Title: An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19
doi: 10.1016/j.dsx.2022.102396
Figure Lengend Snippet:
Article Snippet: For example-primary outcome was all-cause hospitalization or
Techniques: Bioprocessing
Journal: Diabetes & Metabolic Syndrome
Article Title: An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19
doi: 10.1016/j.dsx.2022.102396
Figure Lengend Snippet:
Article Snippet: For example-primary outcome was all-cause hospitalization or
Techniques: Infection
Journal: World Journal of Gastroenterology
Article Title: Endothelial cells and blood vessels are major targets for COVID-19-induced tissue injury and spreading to various organs
doi: 10.3748/wjg.v28.i3.275
Figure Lengend Snippet: Sequential steps of SARS-CoV-2 infection of endothelial cells and endothelial damage. SARS-CoV-2 infects endothelial cells (ECs) using the host angiotensin-converting enzyme 2 receptors and cellular proteases (transmembrane serine protease 2, and cathepsin B and L). The virus then replicates within the cells and is released into the blood vessels, which then disseminate the virus to distant organs. Severe COVID-19 results in a cytokine storm wherein there is increased production of pro-inflammatory cytokines such as interleukin-6 (IL-6), IL-1, interleukin-1 β (IL-1 β) and tumor necrosis factor-α (TNF-α), and results in endothelial damage and endotheliitis, and demonstrated increased vascular permeability that cause plasma extravasation. Activated ECs produce increased amounts of vWF and factor VIII, and PAI-1, which induce a pro-coagulant, hypofibrinolytic state. SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; ECs: Endothelial cells; ACE2: Angiotensin-converting enzyme 2; TMPRSS-2: Transmembrane serine protease 2; CTSB: Cathepsin B; CTSL: Cathepsin L; IL: Interleukin; TNF-α: Tumor necrosis factor-α.
Article Snippet: We wish to add to this list additional investigational treatments in ongoing clinical trials (Table ) and describe two additional oral drugs that were announced in early November 2021 as potential
Techniques: Infection, Permeability